“Switch off/switch on” regulation of drug cytotoxicity by conjugation to a cell targeting peptide
- 1 October 2014
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 85, 139-146
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Antibody-drug conjugates in cancer therapy filling in the potholes that lie aheadOA Cancer, 2013
- Drug resistance to chlorambucil in murine B-cell leukemic cells is overcome by its conjugation to a targeting peptideAnti-Cancer Drugs, 2013
- Targeted drug delivery for cancer therapy: the other side of antibodiesJournal of Hematology & Oncology, 2012
- Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid TumorsMolecular Cancer Therapeutics, 2012
- Novel design principles enable specific targeting of imaging and therapeutic agents to necrotic domains in breast tumorsBreast Cancer Research, 2010
- Synthetic therapeutic peptides: science and marketDrug Discovery Today, 2010
- Tumour-targeted nanomedicines: principles and practiceBritish Journal of Cancer, 2008
- Therapeutic Nanoparticles for Drug Delivery in CancerClinical Cancer Research, 2008
- Targeting small-cell lung cancer with novel fluorescent analogs of somatostatinLung Cancer, 2005
- Immunosuppressors and reversion of multidrug-resistanceCritical Reviews in Oncology/Hematology, 2005